期刊文献+

结核分枝杆菌Rv2629基因产物的亚细胞定位和穿梭质粒转化耻垢分枝杆菌 被引量:1

Subcellular location of Rv2629 in M.tuberculosis and its transformed version into M.smegmatis using the pMV261 plasmid
下载PDF
导出
摘要 目的研究结核分枝杆菌利福平耐药相关蛋白Rv2629在细胞内的亚定位及其与药敏的相关性。方法采用差速离心进行细胞组分分离及蛋白质印迹法(Western blot)检测初步判定蛋白亚细胞定位;采用pMV261转化耻垢分枝杆菌,BACTEC MGIT960测定转化菌株的利福平耐受性。结果Rv2629蛋白主要定位于结核分枝杆菌的细胞壁和细胞膜,重组有Rv2629突变位点191C质粒的耻垢分枝杆菌对利福平的最低抑菌浓度(MIC)为160mg/L,相应的携带有野生型基因191A的宿主菌MIC为20mg/L。结论Rv2629基因191A/C突变同利福平耐药相关。 Objective To detect the subcellular location of Rv2629 in M. tuberculosis, and to test the drug susceptibility of M. smegmatis following the introduction of Rv2629 using the pMV261 plasmid.Methods Different components of M. tuberculosis were separated by differential velocity centrifugation, and subcellular location of Rv2629 was examined by Western blot. The pMV261 plasmid was used to transformM, smegmatis so that it contained the Rv2629 gene. Rifampicin (RIF) resistance was assayed using a BACTEC MGIT 960 instrument. Results Rv2629 was found mainly in the cell wall and cell membrane of M. tuberculosis. The minimum inhibitory concentration (MIC) of RIF for the transformed M. smegmatis containing the mutated Rv2629 gene (strain 191C) was 160 mg/L, while the MIC for the wild type Rv2629 gene (strain 191A) was 20 mg/L, similar to the parental strain. Conclusion These results indicate that the 191A/C mutation of Rv2629 gene is associated with RIF resistance.
出处 《微生物与感染》 2008年第2期90-93,106,共5页 Journal of Microbes and Infections
基金 国家973国家基础研究计划(No2002CB512804 2005CB523102) 国家863高新技术发展计划(No2006AA02Z445)
关键词 结核分枝杆菌 Rv2629 亚细胞定位 穿梭质粒pMV261 药敏试验 M. tuberculosis Rv2629 Subcellular location Shuttle plasmid pMV261 Drag susceptibility testing
  • 相关文献

参考文献15

  • 1WHO. Global tuberculosis control: surveillance, planning, financing: WHO report 2007. Geneva, 2007 : 3 - 99
  • 2Telenti A, Imboden P, Marchesi F, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet, 1993,341:647-650
  • 3Miller N, Hemandez SG, Cleary TJ. Evaluation of Gen-Probe amplified mycobacterium tuberculosis direct test and PCR for direct detection of Mycobactefium tuberculosis in clinical specimens. J Clin Microbiol, 1994,32:393-397
  • 4Zhang Y, Telenti A. Genetics of drug resistance in Mycobacterium tuberculosis. Molecular genetics of mycobaeteria, In: Haffull GF ed. Washington, DC: ASM Press, 2000.235-254
  • 5Wang Q, Yue J, Zhang L, et al. A newly identified 191C/A mutation in the Rv2629 gene was significantly associated with the rifampin resistance in Mycobacterium tuberculosis.J Protome Res,2(I)7,6:4564-4571
  • 6Kwasi G, Mawuenyega C, Forst V, et al. Mycobacterium tuberculosis functional network analysis by global subcellular protein profiling. Mol Biol Cell, 2005,16: 396-404
  • 7Stover CK,Delacruz VF,Fuerst TR,et al. New use of BCG for recombinant vaccines. Nature, 1991,351:456-460
  • 8Obata S, Zwolska Z, Toyota E, et al. Association of rpoB mutations with rifampicin resistance in Mycobaeterium avium. Int J Antimicrob Agents,2006,27:32-39
  • 9Williams D, Spring L, Collins C, et al. Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium trberculosis.Antimicrob Agents Chemother, 1998,42:1853-1857
  • 10Cole ST, Brosch R,Parkhill J,et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature, 1998,393:537-544

同被引文献2

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部